- Home
- IVR vs RIGL Comparison
IVR vs RIGL Comparison
Compare IVR & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVR
- RIGL
- Stock Information
- Founded
- IVR 2008
- RIGL 1996
- Country
- IVR United States
- RIGL United States
- Employees
- IVR N/A
- RIGL N/A
- Industry
- IVR Real Estate Investment Trusts
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- IVR Real Estate
- RIGL Health Care
- Exchange
- IVR Nasdaq
- RIGL Nasdaq
- Market Cap
- IVR 515.0M
- RIGL 486.4M
- IPO Year
- IVR 2009
- RIGL 2000
- Fundamental
- Price
- IVR $8.18
- RIGL $21.81
- Analyst Decision
- IVR Buy
- RIGL Buy
- Analyst Count
- IVR 2
- RIGL 5
- Target Price
- IVR N/A
- RIGL $34.80
- AVG Volume (30 Days)
- IVR 1.8M
- RIGL 347.9K
- Earning Date
- IVR 02-20-2025
- RIGL 03-04-2025
- Dividend Yield
- IVR 19.45%
- RIGL N/A
- EPS Growth
- IVR N/A
- RIGL N/A
- EPS
- IVR 1.23
- RIGL 0.22
- Revenue
- IVR $102,893,000.00
- RIGL $157,374,000.00
- Revenue This Year
- IVR N/A
- RIGL $51.34
- Revenue Next Year
- IVR $8.53
- RIGL $15.75
- P/E Ratio
- IVR $6.68
- RIGL $98.50
- Revenue Growth
- IVR 654.96
- RIGL 21.65
- 52 Week Low
- IVR $7.48
- RIGL $7.48
- 52 Week High
- IVR $9.97
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- IVR 51.78
- RIGL 64.53
- Support Level
- IVR $7.48
- RIGL $17.28
- Resistance Level
- IVR $8.29
- RIGL $18.25
- Average True Range (ATR)
- IVR 0.19
- RIGL 1.37
- MACD
- IVR 0.02
- RIGL 0.65
- Stochastic Oscillator
- IVR 85.80
- RIGL 99.68
About IVR INVESCO MORTGAGE CAPITAL INC
Invesco Mortgage Capital Inc is a REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans. The company's portfolio consists of residential mortgage-backed securities (RMBS) that are guaranteed by a U.S. government agency such as the Government National Mortgage Association, or a federally chartered corporation such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation; Commercial mortgage-backed securities (CMBS) that are not guaranteed by a U.S. government agency or a federally chartered corporation; RMBS that are not guaranteed by a U.S. government agency or a federally chartered corporation; and other real estate-related financing arrangements.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.